Novartis pharmaceuticals news
Novartis disclosed details of a “realignment of resources” within the pharma’s Novartis Institutes for BioMedical Research (NIBR) that is part of a new research strategy for drug discovery. Novartis will merge two early discovery teams to create the new Chemical Biology and Therapeutics (CBT) unit within NIBR. The group will be based in Basel and Cambridge, Mass., and will be integrated with NIBR’s global drug discovery teams. CBT will focus on chemical biology and technologies such as CRISPR, DNA encoded libraries and targeted protein degradation to discover drug targets. The group also will focus on pathway biology and high throughput screening.
Novartis will create biologic “centers of excellence” in Basel and Cambridge, which will explore delivery of biologics. The move will add 20-25 new positions in Basel. The pharma plans to close a biologics group in Shanghai and its ESBATech AG biologics unit in Schlieren, Switzerland. ...